The WAB 2026 Meeting analyzed the latest advances in technologies, biomaterials, and preclinical testing aimed at bringing 3D bioprinting closer to clinical practice and the patient bedside. The event, organized by three PIs from the IDFarma group, brought together national and international experts and featured intense participation and networking. Outstanding plenary speakers were highlighted, along with oral communications by PhD and postdoctoral researchers, showcasing high-impact results and fostering new scientific collaborations.